Home › Compare › PAVMW vs FCPT

PAVMW vs FCPT: Dividend Comparison 2026

PAVMW yields 6896.55% · FCPT yields 6.05%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PAVMW wins by $1432605808592863.25M in total portfolio value
10 years
PAVMW
PAVMW
● Live price
6896.55%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1432605808592863.25M
Annual income
$1,392,875,843,310,163,600,000.00
Full PAVMW calculator →
FCPT
FCPT
● Live price
6.05%
Share price
$23.65
Annual div
$1.43
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.1K
Annual income
$5,775.28
Full FCPT calculator →

Portfolio growth — PAVMW vs FCPT

📍 PAVMW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPAVMWFCPT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PAVMW + FCPT cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
PAVMW pays
FCPT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PAVMW
Annual income on $10K today (after 15% tax)
$586,206.90/yr
After 10yr DRIP, annual income (after tax)
$1,183,944,466,813,639,000,000.00/yr
FCPT
Annual income on $10K today (after 15% tax)
$514.49/yr
After 10yr DRIP, annual income (after tax)
$4,908.99/yr
At 15% tax rate, PAVMW beats the other by $1,183,944,466,813,639,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PAVMW + FCPT for your $10,000?

PAVMW: 50%FCPT: 50%
100% FCPT50/50100% PAVMW
Portfolio after 10yr
$716302904296431.63M
Annual income
$696,437,921,655,081,800,000.00/yr
Blended yield
97.23%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on FCPT right now

PAVMW
Analyst Ratings
4
Buy
Consensus: Buy
Altman Z
-11.3
Piotroski
3/9
FCPT
Analyst Ratings
5
Buy
10
Hold
Consensus: Hold
Price Target
$27.00
+14.2% upside vs current
Range: $25.00 — $29.00
Altman Z
1.4
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PAVMW buys
0
FCPT buys
0
No recent congressional trades found for PAVMW or FCPT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPAVMWFCPT
Forward yield6896.55% ✓6.05%
Annual dividend / share$2.00 ✓$1.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$1432605808592863.25M ✓$49.1K
Annual income after 10y$1,392,875,843,310,163,600,000.00 ✓$5,775.28
Total dividends collected$1429942114786334.00M ✓$24.1K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: PAVMW vs FCPT ($10,000, DRIP)

YearPAVMW PortfolioPAVMW Income/yrFCPT PortfolioFCPT Income/yrGap
1← crossover$700,355$689,655.17$11,401$700.92+$689.0K → PAVMW
2$45,889,900$45,140,520.30$13,064$864.84+$45.88M → PAVMW
3$2,813,379,172$2,764,276,978.38$15,051$1,072.48+$2813.36M → PAVMW
4$161,393,449,836$158,383,134,122.24$17,442$1,337.22+$161393.43M → PAVMW
5$8,664,159,276,546$8,491,468,285,221.65$20,340$1,677.08+$8664159.26M → PAVMW
6$435,300,017,392,982$426,029,366,967,078.00$23,880$2,116.57+$435300017.37M → PAVMW
7$20,469,824,923,231,620$20,004,053,904,621,130.00$28,241$2,689.36+$20469824923.20M → PAVMW
8$901,046,035,934,427,400$879,143,323,266,569,700.00$33,660$3,442.07+$901046035934.39M → PAVMW
9$37,130,808,675,420,410,000$36,166,689,416,970,576,000.00$40,456$4,439.95+$37130808675420.38M → PAVMW
10$1,432,605,808,592,863,400,000$1,392,875,843,310,163,600,000.00$49,063$5,775.28+$1432605808592863.25M → PAVMW

PAVMW vs FCPT: Complete Analysis 2026

PAVMW — Stock

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE). Its product pipeline also comprises EsoGuard, a molecular diagnostic esophageal DNA test; EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; PortIO, an implantable intraosseous vascular access device; and DisappEAR, a resorbable pediatric ear tube, as well as NextCath and Caldus. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is based in New York, New York.

Full PAVMW Calculator →

FCPT — REIT

FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the acquisition and leasing of restaurant properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries.

Full FCPT Calculator →
📬

Get this PAVMW vs FCPT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PAVMW vs SCHDPAVMW vs JEPIPAVMW vs OPAVMW vs KOPAVMW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.